FDA-approved GHRH analogue that targets visceral fat in HIV-associated lipodystrophy.
Typical dose range: 1–2 mg
Frequency: Daily
Route: Subcutaneous
Half-life: ~26 min
Evidence level: Clinical (FDA)
Strongest evidence base of any GHRH. Off-label use for stubborn visceral fat is increasingly common.